Hero

Celyad Receives €8.5 Million in Grants and Non-Dilutive Funding by the Walloon Region

1

Celyad Receives €8.5 Million in Grants and Non-Dilutive Funding by the Walloon Region

Celyad Announces Third Quarter 2019 Financial Results and Recent Business Highlights

2

Celyad Announces Third Quarter 2019 Financial Results and Recent Business Highlights

Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Therapy for mCRC, from SITC 34th Annual Meeting

3

Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Therapy for mCRC, from SITC 34th Annual Meeting

Celyad to Present Update to r/r AML and MDS Program at 2019 ASH Annual Meeting

4

Celyad to Present Update to r/r AML and MDS Program at 2019 ASH Annual Meeting

Celyad Announces October and November 2019 Investor Conference Schedule

5

Celyad Announces October and November 2019 Investor Conference Schedule

About Celyad

Making the Impossible Possible

Celyad is a clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.

Latest News

Celyad Receives €8.5 Million in Grants and Non-Dilutive Funding by the Walloon Region

Celyad Receives €8.5 Million in Grants and Non-Dilutive Funding by the Walloon Region

Celyad Announces Third Quarter 2019 Financial Results and Recent Business Highlights

Celyad Announces Third Quarter 2019 Financial Results and Recent Business Highlights

Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Therapy for mCRC, from SITC 34th Annual Meeting

Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Therapy for mCRC, from SITC 34th Annual Meeting

Discover all news

Carousel

Social Feed

RT @redacTendances: Coup de pouce wallon pour #Celyad https://t.co/FlX4DdV6Ux @CelyadSA

8 hours ago

RT @redacTendances: Coup de pouce wallon pour #Celyad https://t.co/FlX4DdV6Ux @CelyadSA

Celyad Receives €8.5 Million in Grants and Non-Dilutive Funding by the Walloon Region. $CYAD @Wallonie_SPW… https://t.co/DiThkLPf2v

12 hours ago

Celyad Receives €8.5 Million in Grants and Non-Dilutive Funding by the Walloon Region. $CYAD @Wallonie_SPW… https://t.co/DiThkLPf2v

Filippo Petti, Celyad's CEO, and David Gilham, VP R&D are attending Jefferies 2019 London Healthcare conference tod… https://t.co/8ZXcU53PEy

1 day ago

Filippo Petti, Celyad's CEO, and David Gilham, VP R&D are attending Jefferies 2019 London Healthcare conference tod… https://t.co/8ZXcU53PEy

Today, Dr Peggy Sotiropoulou, R&D Director at Celyad, gives a presentation at PEGS Europe ! https://t.co/qR6wyQJo9F… https://t.co/oSmc5JkR91

2 days ago

Today, Dr Peggy Sotiropoulou, R&D Director at Celyad, gives a presentation at PEGS Europe ! https://t.co/qR6wyQJo9F… https://t.co/oSmc5JkR91

RT @redacTendances: Coup de pouce wallon pour #Celyad https://t.co/FlX4DdV6Ux @CelyadSA

8 hours ago

RT @redacTendances: Coup de pouce wallon pour #Celyad https://t.co/FlX4DdV6Ux @CelyadSA

Celyad Receives €8.5 Million in Grants and Non-Dilutive Funding by the Walloon Region. $CYAD @Wallonie_SPW… https://t.co/DiThkLPf2v

12 hours ago

Celyad Receives €8.5 Million in Grants and Non-Dilutive Funding by the Walloon Region. $CYAD @Wallonie_SPW… https://t.co/DiThkLPf2v

Filippo Petti, Celyad's CEO, and David Gilham, VP R&D are attending Jefferies 2019 London Healthcare conference tod… https://t.co/8ZXcU53PEy

1 day ago

Filippo Petti, Celyad's CEO, and David Gilham, VP R&D are attending Jefferies 2019 London Healthcare conference tod… https://t.co/8ZXcU53PEy

Today, Dr Peggy Sotiropoulou, R&D Director at Celyad, gives a presentation at PEGS Europe ! https://t.co/qR6wyQJo9F… https://t.co/oSmc5JkR91

2 days ago

Today, Dr Peggy Sotiropoulou, R&D Director at Celyad, gives a presentation at PEGS Europe ! https://t.co/qR6wyQJo9F… https://t.co/oSmc5JkR91